Vaccines

With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.

The mRNA-1647 vaccine demonstrated approximately a 50% efficacy against human cytomegalovirus (HCMV).

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

Study will determine the effectiveness of vaccine in preventing invasive pneumococcal disease.

This news comes after the World Health Organization (WHO) recently granted the vaccine an emergency use listing (EUL), and continues to become available to more countries.

A new study reveals that the cholera vaccine's diminished efficacy highlights the need for improved strategies in combating a global health challenge.

The National Foundation for Infectious Diseases (NFID) medical director weighs in on this year’s respiratory virus season and offers some strategies to prevent transmission.

New study reinforces the importance of early detection and vaccination against bacterial meningitis.

Changes encompass clarification of recommendations for scheduled vaccinations and the addition of the RSV vaccines for the first time.

With it comes the possibility for international cooperation regarding an investigational Middle East Respiratory Syndrome (MERS) vaccine.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

The city’s health department posted a statement on the recent events, and a new JAMA commentary from FDA leadership reminds the public that vaccine preventable diseases remain a health threat.

A study used real-world CDC data to calculate the number of people who needed to be vaccinated to prevent both medical events in the greater community.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

A clinician discusses the vaccines' efficacy, which risk factors may rank higher for disease severity, and offers insights on counseling patients.

The emergency use listing (EUL) now provides another option for those who are in World Health Organization (WHO) member states.

Topline data results from the company’s phase 3 trial, STRIDE-3, were announced and will be presented at the World Vaccine Congress West Coast.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

The Pfizer product is indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

The federal agency says the data shows immunization reduces hospitalizations by more than 57 percent in first 6 months after birth.